Stammdaten
Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.
Unternehmen & Branche
| Name | Nasus Pharma Ltd |
|---|---|
| Ticker | NSRX |
| CIK | 0002029039 |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | M7071P109 |
|---|---|
| ISIN | USM7071P1095 |
| Typ | ORD SHS |
| Marktkapitalisierung | 25,2 Mio. USD |
| Beta | 5,02 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| MORGAN STANLEY | 2,000 | 0 | 2,000 | 18,300 | Neu | +100,0% | |
| UBS Group AG | 378 | 0 | 378 | 3,459 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | Teleman Dan Benjamin | Director, Officer, Chief Executive Officer | Open Market Purchase | 2,900 | 3.76 | 10,904.00 | +52,5% | |
| 2026-03-31 | Teleman Dan Benjamin | Director, Officer, Chief Executive Officer | Open Market Purchase | 15,000 | 2.04 | 30,600.00 | +147,5% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-03-27 | 119 | 2,40 | 286 |
| 2026-03-24 | 41 | 2,50 | 103 |
| 2026-03-20 | 29 | 2,48 | 72 |
| 2026-03-19 | 180.773 | 2,62 | 473.625 |
| 2026-03-18 | 276.233 | 2,79 | 770.690 |
| 2026-03-17 | 350.156 | 3,10 | 1.085.484 |
Top-Fondshalter
Hinweis: Keine aktuelleren Daten zu dieser Aktie verfuegbar. Stand der gezeigten 13F-Holdings: 31.12.2025. Letztes global veroeffentlichtes 13F-Quartal: 31.03.2026.
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| MORGAN STANLEY | 2,000 | 18,300 | 84.10 |
| UBS Group AG | 378 | 3,459 | 15.90 |